Evaluation of the Effect of Naloxegol on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT/QTc Study in Healthy Volunteers

Naloxegol at 25 and 150 mg was not associated with QT/QTc interval prolongation in these healthy men, and at the proposed therapeutic dose of 25 mg/d, naloxegol is not expected to have a clinically relevant effect on cardiac repolarization in patients with OIC. ClinicalTrials.gov identifier: NCT01325415.